Replies to post #724070 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Investor082,

You do not know whether Merck or BMS or any other company is interested in NWBO, but we do know that BP companies follow clinical trials and they read the peer-reviewed medical literature—they reference and cite clinical data and peer review all the time. We don’t have insider information, but we do have publicly available facts to consider with regard to the overall PD-1 market and all of the BP companies that have or are developing PD-1 drugs.

DC technologies owned by NWBO are being investigated in combo with several BP products at UCLA and at Roswell, including Merck’s pembrolizumab.

Relatively recently, Merck hired an expert in dendritic cell technology (Dr. Butterfield).

Combining PD-1 blockade with dendritic cell vaccines is a relatively new idea. The combo trials at UCLA and Roswell have reached PII, and data are beginning to emerge. PD-1 technology has only been commercially available for 10 years and the drug class is growing along with its demand globally.

⭐️Combo is King!⭐️

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175085456

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175182311

[dstock07734]

If you were able to predict how BPs would act, you wouldn't end up roaming on this board like a clown.

[flipper44]

Incorrect. It looks like what they could have said is we’ll wait to see if:

1. You get two approvals.
2. The combo trial is obvious.
3. Flaskworks commercial version is ready to test.

Discussions weren’t just talked about at the June 2024 ASM, this was waiting MAA “cement to cure” 21 months prior, at the December 2022 ASM. I don’t consider forward looking statements on collaboration/partnering potential discussions to be a joke.

So actually, while the Prometheus timeline can be instructive, it seems to me they should be way ahead of that timeline.

Prometheus had a limited oncology pipeline, whereas NWBO’s is broad spectrum. Prometheus’ most promising product was in a 2b trial. DCVax-l is nearly commercialized.